Plasma levels of YKL‑40 as a prognostic factor in childhood acute lymphoblastic leukemia

YKL-40, also known as chitinase-3-like protein 1 (CHI3L1), is an inflammatory glycoprotein secreted by different types of cells, such as inflammatory cells. The levels of this protein are elevated in the serum or plasma of patients with different types of cancer, and high concentrations are associat...

Full description

Saved in:
Bibliographic Details
Published inMolecular and clinical oncology Vol. 15; no. 2
Main Authors Rivas-Alarcon, Alinne Ayulieth, Gomez-Gomez, Yazmin, Organista-Nava, Jorge, Jimenez-Lopez, Marco Antonio, Rivera-Ramirez, Ana Berta, Ibarra-Sierra, Eloisa, Saavedra-Herrera, Monica Virginia, Illades-Aguiar, Berenice, Leyva-Vazquez, Marco Antonio
Format Journal Article
LanguageEnglish
Published Athens Spandidos Publications 01.08.2021
Spandidos Publications UK Ltd
D.A. Spandidos
Subjects
Acute lymphocytic leukemia
Age
Biomarkers
Cancer
Cancer patients
Children
Disease
Endometrial cancer
Enzyme-linked immunosorbent assay
Ethylenediaminetetraacetic acid
Health aspects
Health care
Inflammation
Leukemia
Medical prognosis
Oncology
Pediatrics
Plasma
Prognosis
Proteins
Regression analysis
Statistical analysis
Vincristine
Mexico
Online AccessGet full text

Cover

More Information
Summary:YKL-40, also known as chitinase-3-like protein 1 (CHI3L1), is an inflammatory glycoprotein secreted by different types of cells, such as inflammatory cells. The levels of this protein are elevated in the serum or plasma of patients with different types of cancer, and high concentrations are associated with poor prognosis and short survival in patients with liver, breast, lung, bladder and endometrial cancers. In Mexico, acute lymphoblastic leukemia (ALL) is the most common type of cancer affecting the pediatric population. The prognosis of patients with ALL is difficult to establish. Hence, the objective of the present study was to analyze the plasma levels of YKL-40 in Mexican children with ALL and investigate its role as a prognostic factor. A case-control study was performed in a population of 90 children aged 1-18 years, among whom 45 had ALL and 45 were hematologically healthy. The levels of YKL-40 in plasma samples were measured using ELISA and were found to be significantly higher in children with ALL compared with those in controls (P<0.0001). Children with ALL who had high plasma levels of YKL-40 ([greater than or equal to] 36.34 ng/ml) had shorter survival compared with those with low levels (<36.34 ng/ml; P<0.05). The findings of the present study revealed that the YKL-40 plasma level, age/initial leukocyte count and central nervous system invasion were associated with the prognosis of children with ALL [odds ratio (OR)=6.06, 95% confidence interval (CI): 1.1-31.6, P=0.03; OR=8.53, 95% CI: 1.2-58.2, P=0.03; and OR=6.45, 95% CI: 1.01-41.2, P=0.04, respectively]. Therefore, YKL-40 plasma levels may serve as a prognostic biomarker in pediatric patients with ALL. Key words: acute lymphoblastic leukemia, childhood, YKL-40, prognosis, survival
ISSN:2049-9450
2049-9469
DOI:10.3892/mco.2021.2330